Harvard Apparatus Regenerative Technology, Inc.
Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage biotechnology company that develops regenerative medicine treatments for disorders of the gastro-intestinal tract and airways. It also operates a consumer health products business in Hong Kong that sells dietary supplements online to consumers in Asia.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDevelopment-stage therapies intended to restore organ function in the GI tract and airways.
Research programs focused on scaffold materials, cellularization, and preclinical validation.
Dietary supplements and personal healthcare products sold through the Hong Kong subsidiary.
Customers
The core biotechnology business is aimed at patients with cancers, injuries, or birth defects affecting the gastro-intestinal system and airways, but it is still in development and not yet commercially approved. The commercial revenue base currently comes from consumer health products sold to the general public in Asia through eCommerce. This creates a split model: long-duration clinical development on one side and direct-to-consumer supplement sales on the other.
Future end users of regenerative therapies intended to restore organ function after cancer, trauma, or birth defects.
Buy dietary supplements and consumer health products through online channels from the Hong Kong subsidiary.
Support the company’s development programs by enrolling patients and generating clinical evidence.
Potential future prescribers or adopters of approved regenerative therapies.
Strategy
The company is trying to advance regenerative medicine programs while preserving optionality on where the first commercial approval may come from, including the U.S. or China. In parallel, it is using consumer health products to generate product revenue and maintain a commercial footprint while the core biotech platform remains clinical-stage. Management also indicates that future China development could involve a joint venture tied to the Hong Kong subsidiary.
The company needs a viable approval route before its implant products can become commercial.
The business is cash constrained and needs external funding to continue operations.
Supplement sales provide a commercial revenue stream while biotech programs remain unapproved.
Geography
The company is headquartered in the United States but its commercial consumer health activity is targeted at Asia through eCommerce. Management also highlights China and the U.S. as possible regulatory pathways for its implant products, making geography a key driver of development strategy and approval risk. The Hong Kong subsidiary is important because it provides a near-term commercial channel while the core biotech programs remain pre-approval.
Risks
The company faces substantial going-concern and financing risk because it has limited cash, ongoing operating losses, and no approved regenerative medicine products. Clinical development risk is also high: patient recruitment, trial execution, and regulatory approval timing can materially delay or prevent commercialization. The consumer health business reduces dependence on pure R&D but introduces execution risk in a competitive eCommerce supplement market.
The company expects continued operating losses and needs additional capital to fund operations.
Exposure: Core biotech operations and corporate continuity
Product candidates are not approved anywhere and commercialization depends on successful clearance.
Exposure: Regenerative medicine pipeline
Management notes recruitment challenges and the need to increase trial sites and outreach.
Exposure: Clinical-stage development programs
A China pathway may involve a joint venture, licensing terms, and local regulatory uncertainty.
Exposure: Potential commercialization and financing strategy
Online supplement sales depend on consumer demand, marketing efficiency, and platform visibility.
Exposure: Asia eCommerce supplement business
Accounting
Judgemental itemsClinical and preclinical costs are expensed immediately, so development intensity directly drives reported losses.
Impact: Higher trial activity increases operating loss
Equity awards are embedded in R&D and G&A, affecting non-cash expense and comparability.
Impact: Can materially affect operating loss and dilution analysis
Interest expense and finance charges are meaningful for a cash-constrained company.
Impact: Affects net loss and financing burden
Management states substantial doubt about continuing as a going concern without new capital.
Impact: Important for liquidity assessment and valuation
Similar listed companies
Publicly listed companies with a comparable business focus.
Harvard Bioscience, Inc
HBIO · Laboratory Analytical Instruments
Harvard Bioscience designs, manufactures, and sells life-science research tools used in drug discovery, translational medicine, and preclinical testing.
BioRestorative Therapies, Inc.
BRTX · Services-Misc Health & Allied Services, NEC
Celularity Inc
CELU · Pharmaceutical Preparations
Regenerative Medical Technology Group Inc.
RMTG · Retail-Retail Stores, NEC
International Stem Cell CORP
ISCO · Pharmaceutical Preparations
Cero Therapeutics Holdings, Inc.
CEROW · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026